WO2025003770 - IL-2 FUSION PROTEINS
National phase entry:
Publication Number
WO/2025/003770
Publication Date
02.01.2025
International Application No.
PCT/IB2024/000480
International Filing Date
27.06.2024
Title **
[English]
IL-2 FUSION PROTEINS
[French]
PROTÉINES DE FUSION IL-2
Applicants **
MEDICENNA THERAPEUTICS INC.
Inventors
MERCHANT, Fahar
LIU, Qian
Priority Data
63/510,580
27.06.2023
US
63/594,694
31.10.2023
US
63/595,044
01.11.2023
US
63/595,271
01.11.2023
US
63/575,960
08.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4603 | |
| EPO | Filing, Examination, Granting | 29621 | |
| Japan | Filing, Examination, Granting | 2900 | |
| South Korea | Filing, Examination, Granting | 3729 | |
| USA | Filing, Examination, Granting | 11490 |
Total:
52,343
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein are novel IL-2 fusion proteins that include an IL-2 moiety attached to an IL-2 masking moiety that includes an IL-13 mutein, an IL-13Ra2 binding mutein, an IL-13Ra2 antibody or antigen-binding fragment thereof, an extracellular domain of CD122, an extracellular domain of CD132, or an extracellular domain of CD25 by a protease sensitive linker (PSL). In some embodiments, the IL-2 fusion proteins include an IL-13 mutein or IL-13Ra2 antibody or antigen-binding fragment thereof that is capable of binding to IL- 13Ra2, and does not bind to IL-13Ro1, and the protease sensitive linker is cleavable by a protease in the tumor microenvironment. Such IL-2 fusion proteins are useful, for example, for the treatment of IL-13Ro2 expressing cancers.[French]
L'invention concerne de nouvelles protéines de fusion d'IL-2 qui comprennent une fraction IL-2 fixée à une fraction de masquage d'IL-2 qui comprend une mutéine d'IL-13, une mutéine de liaison à IL-13Ra2, un anticorps IL-13Ra2 ou un fragment de liaison à l'antigène de celui-ci, un domaine extracellulaire de CD122, un domaine extracellulaire de CD132, ou un domaine extracellulaire de CD25 par un lieur sensible à la protéase (PSL). Dans certains modes de réalisation, les protéines de fusion IL-2 comprennent un anticorps mutéine IL-13 ou IL-13Ra2 ou un fragment de liaison à l'antigène de celui-ci pouvant se lier à IL-13Ra2, et qui ne se lie pas à IL-13Ro1, et le PSL est clivable par une protéase dans le microenvironnement tumoral. De telles protéines de fusion d'IL-2 sont utiles, par exemple, pour le traitement de cancers exprimant IL-13Ro2.